利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.031 秒)

    RECOMBINANT ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
    2.
    发明公开
    RECOMBINANT ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 审中-公开
    REKOMBINANTEANTIKÖRPERGEGEN DENVASKULÄREN内皮细胞生长因子（VEGF）

    公开(公告)号：EP2093236A1

    公开(公告)日：2009-08-26

    申请号：EP07817383.8

    申请日：2007-10-30

    申请人： Centro De Ingenieria Genetica Y Biotecnologia

    发明人： LAMDAN ORDÁS, Humberto ,  GAVILONDO COWLEY, Jorge, Víctor ,  AYALA AVILA, Marta ,  ROJAS DORANTES, Gertrudis ,  MORERA DÍAZ, Yanelys ,  GUIROLA CRUZ, Osmany ,  CHINEA SANTIAGO, Glay ,  SANTIAGO VISPO, Nelson, Francisco

    IPC分类号： C07K16/22

    CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00

    摘要： The present invention deals with recombinant polypeptide molecules related to antibodies, that specifically recognize the human Vascular Endothelial Growth Factor A (VEGF-A), and interfere with its in vitro stimulatory effects and pro-angiogenic activity in vivo . These recombinant polypeptide molecules affect proliferation of human endothelial cells in vitro, subcutaneous angiogenesis in mice induced by Matrigel pellets that contain VEGF-A and the growth of human tumors transplanted in nude athymic mice. Several of these moleculas prevent choroideal neovascularization in a non human primate experimental model. These molecules can be employed for passive immunotherapy in pathological entities which have in its base an abnormal increase in blood vessels, as: age-related macular degeneration (wet variant), cancer and its metastases, neovascular glaucoma, diabetic and newborn retinopathies, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, organ transplant rejection, hemangioma, angiofibroma, and others.

    摘要翻译： 本发明涉及与抗体相关的重组多肽分子，其特异性识别人类血管内皮生长因子A（VEGF-A），并且干扰其在体内的体外刺激作用和促血管生成活性。 这些重组多肽分子影响人体内皮细胞的体外增殖，小鼠皮下血管发生，由含有VEGF-A的Matrigel颗粒诱导，以及移植在裸露无胸腺小鼠中的人类肿瘤的生长。 这些分子中的几个在非人类灵长类动物实验模型中阻止了choroideal新生血管形成。 这些分子可用于病理实体中的被动免疫治疗，其基础是血管异常增加，如：年龄相关性黄斑变性（湿性变体），癌症及其转移，新生血管性青光眼，糖尿病和新生儿视网膜病变，急性和 慢性炎症过程，感染性疾病，自身免疫性疾病，器官移植排斥反应，血管瘤，血管纤维瘤等。